



11:14:02

PATENT  
Case: OC01000KQ US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

RYBAK ET AL.

For:

MELANOMA THERAPY

Serial No.: 09/904,263

Filed: July 12, 2001

Examiner: J. HOLLERAN

Group Art Unit: 1642

**RECEIVED**

NOV 08 2002

Assistant Commissioner for Patents  
Washington, D.C. 20231

TECH CENTER 1600/2900

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, DC. 20231 on October 31, 2002

10/31/02  
Date of Deposit

Michael D. Davis  
Registered Representative

Michael D. Davis 10/31/02  
Signature & Date

**RESPONSE TO RESTRICTION REQUIREMENT**

Sir:

In response to the Restriction Requirement, dated October 2, 2002, for the above-identified patent application due November 2, 2002, the Applicants include the election of the invention to be examined, along with a Supplemental Information Disclosure Statement, a Form-PTO 1449, and copies of the art listed that are not currently of record.

The Examiner has required the restriction of the above-identified patent application under 35 U.S.C. § 121 to the following two groups of claims:

(1) Claims 1-17, drawn to methods for treating melanoma, classified in Class 514, subclass 2: and

BEST AVAILABLE COPY

(2) Claims 18-20, drawn to methods for marketing pegylated interferon alpha, unclassified.

In complete response to the Examiner's requirement, the Applicants elect to prosecute Claims 1-17, drawn to methods for treating melanoma, without traverse. Claims 1-17 therefore remain for examination.

#### SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

The Applicants submit the enclosed: (i) Supplemental Information Disclosure Statement, (ii) Form-PTO 1449, and (iii) copies of six references listed (as CC-CH) on the Form-PTO 1449, not currently of record. The Applicants have corrected typographical errors on the Form-PTO 1449 (in bold) and have more particularly identified three Abstracts as BR1, BR2, and BR3 respectively. These three Abstracts had been collectively identified as document BR on the earlier-filed Form-PTO 1449. The Applicants also resubmit a copy of a single page reference that comprises these three Abstracts for the Examiner's convenience.

No fees are believed to arise due to this filing, however, if any fees are required, the Commissioner is hereby authorized to charge any required fees to Deposit Account No. 19-0365.

The Applicants believe that the next step in the prosecution of this Application should be in the form of a Notice of Allowance and such action is respectfully solicited.

**BEST AVAILABLE COPY**

If the Examiner should have any questions regarding this Amendment and/or patent Application, she is encouraged to contact the undersigned attorney.

Respectfully submitted,



Michael D. Davis  
Attorney for Applicant(s)  
Registration No.: 39,161  
Telephone No.: (908) 298-2194

SCHERING-PLOUGH  
CORPORATION  
Patent Department, K-6-1, 1990  
2000 Galloping Hill Road  
Kenilworth, New Jersey 07033-0530  
Date: October 31, 2002

**BEST AVAILABLE COPY**